Your search for non small cell lung cancer returned 36 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Brian Park, PharmD remove
Older than 2 years remove
Home remove

Your search for non small cell lung cancer returned 36 results

Sort Results:

Relevant Recent

Ramucirumab Plus Erlotinib Evaluated as First-Line Treatment for EGFR-Mutated NSCLC

Results from the phase 3 RELAY trial of ramucirumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) compared with erlotinib alone, according to a study published in The Lancet Oncology. The multicenter, double-blind, placebo-controlled study evaluated the efficacy and…
Drugs in the Pipeline

Cemiplimab Granted Priority Review for Advanced NSCLC

Topline results from the trial showed that compared with chemotherapy, treatment with cemiplimab-rwlc reduced the risk of death by 32% in the overall trial population.

First-Line Atezolizumab Improves Overall Survival in Advanced NSCLC

Genentech announced positive data from the phase 3 IMpower110 study of atezolizumab as first-line monotherapy in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). IMpower110 is an open-label, randomized study comparing the efficacy and safety of atezolizumab monotherapy to chemotherapy consisting of either cisplatin or carboplatin plus…
Drugs in the Pipeline

Cemiplimab NSCLC Trial Stopped Early After Demonstrating Survival Benefit

Sanofi and Regeneron announced that the phase 3 trial evaluating cemiplimab (Libtayo®) as a potential first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer was stopped early due to “highly significant improvement” in overall survival.

Imfinzi Labeling Updated With Overall Survival Data in NSCLC

The Food and Drug Administration (FDA) has approved updated labeling for Imfinzi (durvalumab; AstraZeneca) to include overall survival data for patients with unresectable, Stage III non-small cell lung cancer (NSCLC). The update was based on data from the phase 3, double blind, multicenter PACIFIC trial that evaluated the efficacy of durvalumab  in 713 adult patients…